What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
Where is Radius Health's stock going? Where will Radius Health's stock price be in 2017?
8 equities research analysts have issued 1-year target prices for Radius Health's shares. Their predictions range from $24.00 to $85.00. On average, they expect Radius Health's stock price to reach $57.57 in the next year.
When will Radius Health announce their earnings?
Radius Health is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
According to Zacks Investment Research, "Radius’ lead candidate abaloparatide for subcutaneous (abaloparatide-SC) injection is currently under review in both the U.S. and the EU. A response from the FDA is expected by Mar 30, 2017. An approval of the candidate will significantly boost the growth prospects of the company. However, its dependence on abaloparatide-SC is concerning, as the company has very few late-stage candidates in its pipeline. An unfavorable outcome from any regulatory body will adversely impact the stock. The company’ shares have underperformed the Zacks classified Medical-Drugs industry in the last twelve months. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded given the presence of products like Amgen’s Prolia and Lilly’s Forteo among others." (1/4/2017)
Cantor Fitzgerald analysts commented, "Filing Overhang to Recede. An NDA for abaloparatide-SC has been filed with FDA, following on the European validation of the MAA filing. This suggests to us that the U.S. PDUFA date will be early 2017. The U.S." (3/31/2016)
Who owns Radius Health stock?
Radius Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), State Street Corp (4.37%), Franklin Resources Inc. (1.41%), Fiera Capital Corp (1.09%), Perceptive Advisors LLC (0.61%) and Oxford Asset Management (0.44%). Company insiders that own Radius Health stock include Gary Hattersley, Growth N V Biotech, Kurt Graves and Rob Ward.
Who sold Radius Health stock? Who is selling Radius Health stock?
Radius Health's stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Commerzbank Aktiengesellschaft FI, Franklin Resources Inc., Nicholas Investment Partners LP, AQR Capital Management LLC and Envestnet Asset Management Inc..
Who bought Radius Health stock? Who is buying Radius Health stock?
Radius Health's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Perceptive Advisors LLC, Oxford Asset Management, Marshall Wace LLP, Folger Hill Asset Management LP, Russell Investments Group Ltd., FMR LLC and FNY Partners Fund LP.
How do I buy Radius Health stock?
Shares of Radius Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Radius Health stock cost?
One share of Radius Health stock can currently be purchased for approximately $42.48.